证 券 研 究 报 告 植物护肤心智深入人心，线下门店有量有质 ——从植物医生看化妆品行业发展趋势 证券分析师：王立平 A0230511040052 聂霜 A0230524120002 2025.7.12 摘要 www.swsresearch.com 证券研究报告 2 ◼ 公司深耕中国美妆市场30年，04年开始公司致力于高山植物护肤产品的研发、生产和销售，聚焦于"植物医生"品牌，以"高山植物，纯净美肌" 为定位，国内最大的单体美妆品牌门店连锁之一。公司股权集中，创始人兼董事长解总通过直接与间接的方式合计持股超80%，掌握公司话语权。 2022年至2024年，公司实现营业收入21.2、21.5、21.6亿元，年均复合个位数增长；实现归母净利润1.6、2.3、2.4亿元，年均复合增长率达 24.0%，盈利能力不断增强。产品端品类齐全，水乳膏霜产品营收占半壁江山，精华、面膜等品类齐全。渠道端建立了以经销模式为主、直营模式 为辅、线下线上全面布局的销售模式。 ◼ 化妆品市场稳健增长，发展由"量"向"质"转变。线上线下平衡发展，行业规范化、科技化、国货崛起等为未来发展方向，同时，化妆品出海也 成为行业热门发展方向。20 ...

尹莹/作者 李彦/编辑 化妆品那些事/出品 头图/截自品牌官网 植物医生要上市了。 6月27日，据深交所官网披露，北京植物医生化妆品股份有限公司（以下简称"植物医生"）主板IPO申请获受理，保荐机构为中信证券，企业拟公开发行新股 数量不超过2666.67万股，占本次发行后总股本的比例不低于25%。 据招股书披露的信息，植物医生2022年至2024年间公司分别实现主营业务收入21.16亿元、21.50亿元和21.55亿元，净利润分别为1.68亿元、2.29亿元和2.42亿 元，公司主营业务毛利率分别为55.22%、60.34%和58.90%。截至2025年5月31日，公司拥有481家分公司。 | | | | 里位: 力元 | | --- | --- | --- | --- | | 主营业务收入 | 2024 年度 | 2023 年度 | 2022 年度 | | 其他上市公司中位数 | 137,596.57 | 147,524.18 | 131.107.18 | | 植物医生 | 215,496.81 | 215,000.49 | 211.621.61 | | 净利润 | 2024 年度 | 2023 年度 | ...

Core Viewpoint - The high-end transformation of Shuiyang Group is facing challenges, as evidenced by a significant decline in revenue and profit in the 2024 annual report, raising questions about whether this strategy is beneficial or detrimental to the company [1]. Financial Performance - Shuiyang Group reported a revenue of 4.237 billion yuan in 2024, a year-on-year decrease of 5.69% [1]. - The net profit attributable to shareholders fell by 62.63% to 110 million yuan, while the non-recurring net profit decreased by 56.74% to 118 million yuan [1]. - Sales expenses increased by 11.89% to 2.079 billion yuan, accounting for 49.07% of total revenue [6]. Business Strategy - The company is transitioning to become a "global new luxury beauty group," which involves restructuring its business and increasing investment in high-end brands [1][2]. - Shuiyang Group has made significant acquisitions, including the purchase of the French luxury skincare brand EDB for over 300 million yuan and the acquisition of the American luxury skincare brand RéVive [2][3]. Product Performance - Revenue from self-owned brands reached 1.651 billion yuan, representing approximately 38.97% of total revenue, with a gross margin of 74.27% [3]. - All product categories, including creams, masks, and brand management services, experienced revenue declines, with creams generating 3.351 billion yuan (down 4.38%) and masks generating 734 million yuan (down 10.8%) [4][5]. Research and Development - R&D expenses increased by only 7.32% to 82.1755 million yuan, indicating a lower investment compared to sales expenses [7]. - The company has established a stock incentive plan, but it failed to meet performance targets, resulting in the cancellation of unvested shares for 258 individuals [7][8].